Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement

  • Kline, A.D.
  • Moss, J.F.
  • Selicorni, A.
  • Bisgaard, A.M.
  • Deardorff, M.A.
  • Gillett, P.M.
  • Ishman, S.L.
  • Kerr, L.M.
  • Levin, A.V.
  • Mulder, P.A.
  • Ramos, F.J.
  • Wierzba, Jl
  • Ajmone, P.F.
  • Axtell, D.
  • Blagowidow, N.
  • Cereda, A.
  • Costantino, A.
  • Cormier-Daire, V.
  • FitzPatrick, D.
  • Grados, M.
  • Groves, L.
  • Guthrie, W.
  • Huisman, S.
  • Kaiser, F.J.
  • Koekkoek, G.
  • Levis, M.
  • Mariani, M.
  • McCleery, J.P.
  • Menke, L.A.
  • Metrena, A
  • O'Connor, J.
  • Oliver, C.
  • Pie, J.
  • Piening, S.
  • Potter, C.J.
  • Quaglio, A.L.
  • Redeker, E.
  • Richman, D.
  • Rigamonti, C.
  • Shi, A.
  • Tümer, Z.
  • Van Balkom, I.D.C.
  • Hennekam, R.C.
Cornelia de Lange syndrome (CdLS) is an archetypical genetic syndrome that is characterized by intellectual disability, well-defined facial features, upper limb anomalies and atypical growth, among numerous other signs and symptoms. It is caused by variants in any one of seven genes, all of which have a structural or regulatory function in the cohesin complex. Although recent advances in next-generation sequencing have improved molecular diagnostics, marked heterogeneity exists in clinical and molecular diagnostic approaches and care practices worldwide. Here, we outline a series of recommendations that document the consensus of a group of international experts on clinical diagnostic criteria, both for classic CdLS and non-classic CdLS phenotypes, molecular investigations, long-term management and care planning.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Health care services use among long-term breast cancer survivors: a systematic review

  • Jansana, A.
  • Posso, M.
  • Guerrero, I.
  • Prados-Torres, A.
  • Del Cura, M.I.
  • Castells, X.
  • Sala, M.
Purpose: Long-term breast cancer survivors are women surviving at least 5 years after diagnosis. This systematic review aimed to summarize the main characteristics and patterns of healthcare service use (frequency of visits, health providers visited, and preventive care performed) among long-term breast cancer survivors. Methods: We used standard Cochrane Collaboration methods and searched the MEDLINE and EMBASE databases up to January 2018. We included English language observational studies reporting health service use among long-term cancer survivors. The quality of the studies was appraised through the ROBINS-I assessment tool. Two independent reviewers performed both the study quality assessment and the data extraction. Results: A total of 23 observational studies were included that reported data on health services use by long-term breast cancer survivors. Despite heterogeneity among studies, about half of them reported that breast cancer survivors visited a medical provider at least once a year, as recommended by breast cancer survival guidelines. Although survivors visited medical providers with the recommended frequency, a substantial number used specialist care instead of primary care during follow-up. The results showed underuse of the recommended annual mammogram. Conclusions: Long-term breast cancer survivors differ in their health services use with regard to the frequency of visits as well as the health providers seen. Our results indicate the need for active surveillance through primary care providers in coordination with specialized care. Implications for cancer survivors: This review could help to standardize the management of breast cancer survivors and decision-makers to adapt their guidelines and clinical protocols.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma

  • Santofimia-Castaño, P.
  • Xia, Y.
  • Peng, L.
  • Velázquez-Campoy, A.
  • Abián, O.
  • Lan, W.
  • Lomberk, G.
  • Urrutia, R.
  • Rizzuti, B.
  • Soubeyran, P.
  • Neira, J.L.
  • Iovanna, J.
Cancer cells activate stress-response mechanisms to adapt themselves to a variety of stressful conditions. Among these protective mechanisms, those controlled by the stress-induced nuclear protein 1 (NUPR1 ) belong to the most conserved ones. NUPR1 is an 82-residue-long, monomeric, basic and intrinsically disordered protein (IDP), which was found to be invariably overexpressed in some, if not all, cancer tissues. Remarkably, we and others have previously showed that genetic inactivation of the Nupr1 gene antagonizes the growth of pancreatic cancer as well as several other tumors. With the use of a multidisciplinary strategy by combining biophysical, biochemical, bioinformatic, and biological approaches, a trifluoperazine-derived compound, named ZZW-115, has been identified as an inhibitor of the NUPR1 functions. The anticancer activity of the ZZW-115 was first validated on a large panel of cancer cells. Furthermore, ZZW-115 produced a dose-dependent tumor regression of the tumor size in xenografted mice. Mechanistically, we have demonstrated that NUPR1 binds to several importins. Because ZZW-115 binds NUPR1 through the region around the amino acid Thr68, which is located into the nuclear location signal (NLS) region of the protein, we demonstrated that treatment with ZZW-115 inhibits completely the translocation of NUPR1 from the cytoplasm to the nucleus by competing with importins.